GGrantIndex
← Leaderboards

Alfred E Chang

University Of Michigan At Ann Arbor

$7,481,608
Attributed
$7,481,608
Total exposure
16
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.7M · FY200515
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15

Funding mix

By agency

NIH$11,760,990 · 17

By mechanism

P01$4,460,380 · 5
R01$3,695,276 · 2
T32$3,068,834 · 2
R56$339,500 · 1
P30$197,000 · 3
M01$0 · 4

Top collaborators

No co-investigators on record.

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “Neoplasm /Cancer Immunotherapy

Research focus

Neoplasm /Cancer ImmunotherapyHuman Therapy EvaluationCytokineHuman SubjectLymph NodesTumor AntigensPassive ImmunizationT LymphocyteLeukocyte Activation /TransformationNeoplasm /Cancer VaccineClinical ResearchTissue /Cell CultureLaboratory MouseCd3 MoleculeSurgical OncologyTraining ProgramsResearch TrainingCellular ImmunityMonoclonal AntibodyMichiganPatient Oriented ResearchCryopreservationFlow CytometryUniversities

Grant awards (55)

University of Michigan Surgical Oncology Research Training Program$255,898
T32 · FY2015 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$262,361
T32 · FY2014 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$241,071
T32 · FY2013 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$197,164
T32 · FY2012 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$241,600
T32 · FY2011 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$236,470
T32 · FY2010 · CA · contact PI
IMMUNOLOGICAL MONITORING$54,015
P30 · FY2010 · CA · contact PI
T and B cell Activation of Cancer Immunotherapy$339,500
R56 · FY2009 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$224,090
T32 · FY2009 · CA · contact PI
IMMUNOLOGICAL MONITORING$53,669
P30 · FY2009 · CA · contact PI
T Cell Activation for Cancer Immunotherapy$314,970
R01 · FY2008 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$111,087
T32 · FY2008 · CA · contact PI
IMMUNOLOGICAL MONITORING$29,772
P30 · FY2008 · CA · contact PI
T Cell Activation for Cancer Immunotherapy$315,302
R01 · FY2007 · CA · contact PI
T Cell Therapy of Human Renal Cell Cancer$237,045
R01 · FY2007 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$206,884
T32 · FY2007 · CA · contact PI
IMMUNOLOGICAL MONITORING$29,772
P30 · FY2007 · CA · contact PI
T Cell Activation for Cancer Immunotherapy$325,053
R01 · FY2006 · CA · contact PI
T Cell Therapy of Human Renal Cell Cancer$295,170
R01 · FY2006 · CA · contact PI
University of Michigan Surgical Oncology Research Training Program$178,639
T32 · FY2006 · CA · contact PI
IMMUNOLOGICAL MONITORING$29,772
P30 · FY2006 · CA · contact PI
Cellular Vaccines for Cancer Therapy$1,536,897
P01 · FY2005 · CA
T Cell Activation for Cancer Immunotherapy$333,206
R01 · FY2005 · CA
T Cell Therapy of Human Renal Cell Cancer$302,699
R01 · FY2005 · CA
RESEARCH TRAINING IN TRANSLATIONAL TUMOR IMMUNOLOGY$259,776
T32 · FY2005 · CA
Surgical Oncology Research Training Program$220,920
T32 · FY2005 · CA
Cellular Vaccines for Cancer Therapy$1,493,946
P01 · FY2004 · CA
T Cell Activation for Cancer Immunotherapy$330,547
R01 · FY2004 · CA
Surgical Oncology Research Training Program$242,551
T32 · FY2004 · CA
T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY$308,073
R01 · FY2003 · CA
T Cell Therapy of Human Renal Cell Cancer$53,107
R01 · FY2003 · CA
T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY$300,416
R01 · FY2002 · CA
CORE--IMMUNOLOGY$0
P01 · FY2002 · CA
Immune responses induced by tumor-pulsed dendritic cells$0
P01 · FY2002 · CA
DENDRITIC CELLS ACTIVATED BY GMCSF &IL4 AS A TUMOR VACCINE IN ADVANCED CANCER$0
M01 · FY2002 · RR
IMMUNOTHERAPY OF MELANOMA WITH LYMPH NODE PRIMED WITH GMCSF GENE TRANSDUCED CELL$0
M01 · FY2002 · RR
IMMUNOTHERAPY OF MALIGNACY BY IN VIVO GENE TRANSFER INTO TUMORS$0
M01 · FY2002 · RR
CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES$0
M01 · FY2002 · RR
CORE--IMMUNOLOGIC MONITORING$0
P30 · FY2002 · CA
PILOT--GASTROINTESTINAL ONCOLOGY$0
P30 · FY2002 · CA
CORE--Coordination$0
P01 · FY2002 · CA
T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY$292,979
R01 · FY2001 · CA
Immune responses induced by tumor-pulsed dendritic cells$0
P01 · FY2001 · CA
CORE--IMMUNOLOGIC MONITORING$0
P30 · FY2001 · CA
PILOT--GASTROINTESTINAL ONCOLOGY$0
P30 · FY2001 · CA
CORE--Coordination$0
P01 · FY2001 · CA
CORE--IMMUNOLOGY$0
P01 · FY2001 · CA
GENETIC APPROACHES FOR CANCER IMMUNOTHERAPY$1,248,539
P01 · FY2000 · CA
T CELL ACTIVATION FOR CANCER IMMUNOTHERAPY$286,709
R01 · FY2000 · CA
SURGICAL ONCOLOGY TRAINING IN TUMOR IMMUNOLOGY$190,323
T32 · FY2000 · CA
IMMUNE RESPONSES INDUCED BY GENE TRANSFER$180,998
P01 · FY2000 · CA
IMMUNOTHERAPY OF MALIGNACY BY IN VIVO GENE TRANSFER INTO TUMORS$0
M01 · FY2000 · RR
DENDRITIC CELLS ACTIVATED BY GMCSF &IL4 AS A TUMOR VACCINE IN ADVANCED CANCER$0
M01 · FY2000 · RR
IMMUNOTHERAPY OF MELANOMA WITH LYMPH NODE PRIMED WITH GMCSF GENE TRANSDUCED CELL$0
M01 · FY2000 · RR
CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES$0
M01 · FY2000 · RR